Dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) is a special type of scan used to look at blood flow in the brain. This study is checking if DSC-MRI can help see how well the medicine bevacizumab is working on a kind of brain cancer called glioblastoma when it comes back. Bevacizumab is a drug used to stop the growth of blood vessels that feed tumors.
The study will measure a thing called relative cerebral blood volume (rCBV), which looks at how much blood is in the brain's blood vessels. This trial checks if changes in rCBV can predict how long patients live and how long they stay without the cancer getting worse.
- Patients will have two DSC-MRI scans, one before starting bevacizumab and another 15 days after.
- After the study, follow-ups happen every 3 months for one year, then every 6 months for up to 4 years.
- Participants need to have certain health conditions and cannot have certain allergies or metallic implants due to MRI safety.
How understandable was the trial content above?
Hard to understand
Easy to understand